aslan
pharmaceuticals
initiates
third
dose
cohort
atopic
dermatitis
clinical
trial
aslan
initiated
recruitment
patients
third
dose
cohort
sites
us
australia
singapore
following
successful
safety
review
second
cohort
found
well
tolerated
dose
third
cohort
test
dose
singapore
globe
newswire
aslan
pharmaceuticals
nasdaq
asln
immunology
focused
biopharmaceutical
company
developing
innovative
treatments
transform
lives
patients
today
announced
data
monitoring
committee
dmc
completed
planned
safety
data
review
second
dose
cohort
clinical
trial
moderate
severe
atopic
dermatitis
ad
patients
found
well
tolerated
dmc
recommended
multiple
ascending
dose
mad
clinical
study
continue
planned
aslan
initiated
recruitment
third
highest
dose
cohort
randomised
double
blind
mad
study
total
eight
patients
recruited
clinical
sites
singapore
us
australia
aslan
expects
report
interim
unblinded
data
three
dose
escalation
cohorts
early
dr
ken
kobayashi
chief
medical
officer
aslan
pharmaceuticals
commented
importantly
continues
well
tolerated
patients
treated
study
date
discontinuations
treatment
related
study
drug
observed
following
lifting
recruitment
restrictions
associated
previously
delayed
study
pleased
note
second
dose
cohort
enrolled
eight
patients
around
three
weeks
two
clinical
sites
third
dose
cohort
recruiting
patients
nine
sites
activated
new
sites
australia
us
believe
potential
treatment
patients
ad
look
forward
reporting
data
firming
plans
initiate
phase
study
phase
study
evaluating
three
doses
delivered
subcutaneously
include
fourth
expansion
cohort
dose
cohort
contains
six
patients
two
patients
placebo
expansion
cohort
contain
least
patients
least
six
patients
placebo
patients
dosed
weekly
eight
weeks
determine
safety
tolerability
well
number
secondary
efficacy
outcome
measures
monoclonal
antibody
binds
receptor
subunit
blocking
signalling
two
cytokines
central
triggering
symptoms
ad
redness
itching
skin
media
ir
contacts
emma
thompson
spurwing
communications
tel
email
aslan
robert
uhl
westwicke
partners
tel
email
aslan
pharmaceuticals
aslan
pharmaceuticals
nasdaq
asln
immunology
focused
biopharmaceutical
company
developing
innovative
treatments
transform
lives
patients
led
senior
management
team
extensive
experience
global
development
commercialisation
aslan
clinical
portfolio
comprised
monoclonal
therapy
developed
atopic
dermatitis
immunology
indications
plans
develop
autoimmune
disease
additional
information
please
visit
forward
looking
statements
release
contains
statements
statements
based
current
beliefs
expectations
management
aslan
pharmaceuticals
limited
affiliates
company
statements
may
include
limited
statements
regarding
company
business
strategy
company
plans
develop
commercialise
safety
efficacy
potential
deliver
treatment
people
atopic
dermatitis
company
plans
expected
timing
respect
enrolment
clinical
trials
clinical
trial
results
company
estimates
projections
statements
based
management
current
assumptions
expectations
future
events
trends
affect
may
affect
company
business
strategy
operations
financial
performance
inherently
involve
significant
known
unknown
risks
uncertainties
actual
results
timing
events
could
differ
materially
anticipated
statements
result
risks
uncertainties
include
without
limitation
risk
factors
described
company
securities
exchange
commission
filings
reports
commission
file
including
company
form
filed
securities
exchange
commission
sec
april
statements
statements
historical
fact
statements
words
believe
may
might
could
aim
estimate
continue
anticipate
intend
expect
plan
negative
terms
similar
expressions
convey
uncertainty
future
events
outcomes
intended
identify
estimates
projections
statements
estimates
projections
statements
speak
date
made
except
extent
required
law
company
undertakes
obligation
update
review
estimate
projection
statement
